Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Mira Pharmaceuticals Inc (MIRA)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$0.54-3.71%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MIRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and improve EPS trajectory | A supporting condition in Mira Pharmaceuticals Inc's published investment case. The stated target is EPS loss narrows from -$0.41 toward break-even. | Broken | EPS remains below -$0.41 or worsens next fiscal year | Diluted EPS: $-0.03 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$0.41 toward break-even. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.03 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative development-stage biotech, not a proven earnings compounder. Its programs show preclinical and clinical progress, but the thesis state is insufficient because there is too little recent financial history to judge execution.
The snapshot provides no valuation or expectations evidence, so whether MIRA is cheap, fair, or expensive versus peers cannot be assessed. There is also too little evidence to say what the market already assumes.
Near term, the company remains loss-making: it reported no revenue and a net loss in 2026-Q2, while the latest-quarter miss and smaller-cap status add execution risk. Over the multi-year view, SKNY-1 and MIRA-55 have reported positive preclinical findings, and Ketamir-2 has advanced toward Phase 2a, but none has shown commercial delivery in the evidence provided.
The multi-year thesis depends on whether the drug programs advance through their next development steps and eventually demonstrate commercial potential; the evidence here does not establish that outcome. Near-term sector signals are mixed: strong results from healthcare bellwethers could support the sector backdrop, while weaker jobs data or bellwether setbacks could weaken it; the repeated litigation filings are another concern.
Over the next 1 to 3 years, MIRA remains an uncertain, high-risk development story with program progress but no revenue and limited financial evidence. The long-term thesis hinges on clinical and development execution, alongside risks from litigation and a changing sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stabilize executive leadership after CFO departure | Despite losses, management is improving execution amid volatile CFO changes. | Under Pressure | continued executive turnover or no CFO replacement within 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance clinical development of MIRA-55 and SKNY-1 | MIRA Pharmaceuticals advances its drug pipeline with exclusive rights for MIRA-55 and SKNY-1. | Improving | failure to initiate Phase 2a trial or loss of exclusive rights within next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Unavailable → $-0.16 · observed estimates
$0.04B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-25 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-26 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-27 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-28 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-29 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-30 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-07-31 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-01 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-02 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-03 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-04 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-05 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-06 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-07 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-08 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-09 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-10 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-12 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-13 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-14 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-15 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-16 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-17 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-18 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-19 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-20 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-21 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-22 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-23 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-24 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-25 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-26 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-27 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-28 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-29 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-30 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-08-31 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-01 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-02 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-03 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-04 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-05 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-06 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-07 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-08 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-09 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-10 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-11 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-12 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-13 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-14 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-15 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-16 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-17 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-18 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-19 | Unavailable | $40,000,000 | 0 / 1 |
| 2026-09-20 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-21 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-22 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-23 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-24 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-25 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-26 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-27 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-28 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-29 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-09-30 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-01 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-02 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-03 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-04 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-05 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-06 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-07 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-08 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-09 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-10 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-11 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-12 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-13 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-14 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-15 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-16 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-17 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-18 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-19 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-20 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-21 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-22 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-23 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-24 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-25 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-26 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-27 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-28 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-29 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-30 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-10-31 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-11-01 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-11-02 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-11-03 | $-0.16 | $40,000,000 | 1 / 1 |
| 2026-11-04 | $-0.16 | $40,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.